Redwood City, Calif., January 4, 2023 – Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, today announced the appointment of Julie Anne Smith as Chief Executive Officer (CEO) and member of the Board of Directors. Ms. Smith has over 20 years of experience in the life science…
Physician-scientist and biopharmaceutical executive with extensive experience in novel drug development and pipeline strategy Redwood City, Calif., August 15, 2022 – Nuvig Therapeutics, Inc., a private biotech company developing novel therapeutics to restore immune homeostasis and treat chronic autoimmune diseases, announced today the appointment of Joanne Quan, M.D., as Chief Medical Officer. Dr. Quan has…
Redwood City, Calif., May 11, 2022 – Nuvig Therapeutics, Inc., announced today the launch of the company to develop novel therapeutics that induce mechanisms of immune homeostasis and treat autoimmune diseases without compromising normal immune function. To support this mission, the company has closed a $47 million Series A financing, led by Novo Holdings A/S…